Executive answer
In pharmaceutical and life sciences businesses, a patent is only one part of value creation. Research, clinical trials, regulatory affairs, manufacturing, quality, pharmacovigilance, medical affairs, promotion, market access and payer relationships can affect a product’s Mexican return. Transfer pricing should identify who performs and controls each activity, contributes assets and assumes failure, liability and market risk.
A global royalty on sales may be technically incomplete if the licensed rights, product stage, included services and local contributions are not delineated. Nor should every Mexican expense be presumed routine or every return assigned to the patent’s legal owner.
Organize the analysis by product and lifecycle: research, development, authorization, launch, maturity, new indications, loss of exclusivity and withdrawal. That connects agreements, health-regulatory evidence, financial data and actual conduct.
Product value-chain map
Identify the compound or device, indication, territory, registration holder, IP owner, study sponsor, manufacturer, distributor, promotional entity and medical providers. Record rights, personnel, decisions, assets, investment and revenue.
Separate transactions: license, product purchase, manufacturing, clinical trial, regulatory service, pharmacovigilance, marketing, data, financing and reimbursements. One “regional services” invoice may combine activities with different beneficiaries and methods.
Use milestones such as discovery, clinical phases, filing, registration, pricing, formulary access, launch, expansion, generic or biosimilar entry and end of life. The risk profile changes by stage.
R&D and clinical research
COFEPRIS describes clinical trials as studies evaluating safety, efficacy, tolerance and quality, subject to authorization, monitoring and oversight under the applicable framework. That structure creates activities, decisions and evidence relevant to economic delineation.
Map who designs the protocol, chooses sites, hires investigators, funds, supervises, manages data, approves amendments and can stop the study. Distinguish local execution from strategic and scientific control.
Record outcomes and usage rights. A Mexican entity that coordinates sites may earn a service return; one designing and controlling material elements may contribute more. The answer follows facts, not where expense is booked.
For failed trials, identify who accepted the risk and had financial capacity. Failure is inherent in R&D but does not automatically fall on the legal owner.
Marketing authorization and regulatory affairs
Identify the registration holder, dossier owner, COFEPRIS contact and authority to answer requests. Document who chooses strategy, indication, presentation, changes and renewals.
Registration can be a relevant regulatory asset, but its value depends on rights, exclusivity, transferability and contributions. Do not equate it automatically with a patent or assign the full return to the local holder.
Retain files, approvals, hours, external services and decisions. Routine filing may differ from designing access strategy or generating indispensable evidence.
Manufacturing, quality and supply chain
Map active ingredient, finished product, packaging, release, storage, cold chain and distribution. Identify who sets specifications, approves suppliers, controls batches, chooses inventory and bears recall risk.
Separate design, manufacturing, storage and use defects. Pharmacovigilance and quality may reveal causes, while economic allocation depends on control and agreement.
Analyze expiry obsolescence, regulatory change, forecast errors and market loss. A distributor does not automatically bear all inventory risk because it has physical possession.
Pharmacovigilance and safety
COFEPRIS describes pharmacovigilance in terms of detecting, evaluating, understanding and preventing events and risks related to medicines and vaccines. Determine which entity collects reports, analyzes signals, communicates, decides measures and maintains databases.
Distinguish processing services from control over safety decisions. Document escalation, data access and authority. A withdrawal or label change can affect several markets.
Allocate recall, communication and replacement cost by cause and control, not spending location.
Patents, know-how and other intangibles
Inventory patents, trademarks, registrations, clinical data, know-how, formulations, processes, software, relationships and promotional materials. Record legal owner, developer, funder, controller and exploiter.
Use DEMPE as an interpretive framework for development, enhancement, maintenance, protection and exploitation without replacing Mexican law. Returns should follow contributions and actual control.
A local entity may develop market-access know-how or perform intensive promotion. Determine whether the facts establish services, a marketing-intangible contribution or market risk.
Zugzwang’s Life Sciences TP Review connects product, R&D, regulation, safety, market and intangibles before setting royalties and margins.
Royalties and licenses
Define the licensed rights precisely: patent, trademark, know-how, data, manufacturing, distribution, territory, exclusivity, sublicense and support. Separate included services and goods.
The base may be net sales, units, profit or another measure, but it should match the right and comparables. Review discounts, returns, tax, samples and public sales. Do not copy a database rate without adjusting stage, indication, territory, exclusivity and risk.
Test benefit and ability to pay without making either mechanical. A rate that eliminates all local profit may contradict functions and risk. Review withholding, treaty and deductibility separately.
Promotion and medical affairs
Separate advertising, sales force, medical education, publications, scientific support, samples and post-market studies. Determine objective, audience, approval, control and ownership of output.
Medical affairs should not automatically be grouped with marketing. It may generate evidence, manage scientific information or support safety. Use cost centers and deliverables.
For intensive local promotion, analyze duration, spending, authority and return. Compare what an independent distributor would agree regarding reimbursement, margin and materials.
Market access and payers
Map who develops the economic dossier, value evidence, pricing strategy, negotiations, discounts, tenders and risk-sharing arrangements. These functions may be decisive in monetizing the product.
Document who approves floor prices and concessions. If the principal controls strategy and Mexico executes, remuneration differs from a distributor controlling and assuming the market.
Reconcile rebates and discounts to net sales and the royalty base. Avoid royalties on revenue later reduced without a clear mechanism.
Distribution, samples and inventory
Define ownership, credit, forecasts, expiry, returns, cold chain, destruction and insurance. Segment owned, consigned and purchased product.
Samples need purpose, approval, cost and formula treatment. Near-expiry inventory requires action and evidence of who controlled purchase and demand.
A limited-risk distributor needs a true-up policy operating before royalty, COGS and discounts eliminate its return. The label does not guarantee an outcome.
Method and comparability
Select the method by transaction. A CUP may be relevant for licenses or comparable sales where rights and terms can be adjusted. Resale price may analyze distribution. Cost plus may suit routine services or manufacturing. TNMM requires segmentation and reliable comparables.
Evaluate comparables for stage, portfolio, regulation, exclusivity, R&D, inventory, liability and territory. A mature-product company may not reflect an innovative launch.
Profit split may be considered where both parties make unique and valuable, highly integrated contributions, not as an escape from missing data.
Segmentation and reconciliation
Segment by product, stage and function where material. Allocate promotion, regulatory, medical, sales, quality and shared costs using consumption drivers. Reconcile to financial statements.
Maintain a bridge across gross sales, net sales, discounts, COGS, royalty and margin. Trace regional charges to service and beneficiary.
Do not let mature products silently subsidize launch losses. The final method may use another level, but the file should show cause.
Launches, losses and loss of exclusivity
A launch may require investment before revenue. Document the business case, expected period, decisions and recovery. An initial loss may be market-consistent but is not presumed.
Before loss of exclusivity, model price, volume, inventory, promotion and royalty. A historical rate may cease to be arm’s length when rights and economics change.
At termination, analyze inventory, agreements, people, registration, data and compensation. Do not close the product with an entry alone.
Governance and defense file
Establish a committee spanning business, medical, regulatory, legal, finance and tax. Review milestones, agreements, charges, margin, royalty and risks. Retain contemporaneous decisions.
The file includes the product map, FAR, agreements, registrations, studies, pharmacovigilance, promotion, access, inventory, segmentation, methods and comparables. Cross-reference health files without duplicating protected information.
Control access and privacy. A tax analysis needs sufficient evidence, not unnecessary personal data.
Regional services, benefit and materiality
Groups often centralize regulatory, quality, medical, procurement, data, legal and portfolio management. Inventory each service, provider, recipient, activity, deliverable, cost, allocation key and markup. Do not use a single “management fee” invoice for heterogeneous activities.
Demonstrate that Mexico received a benefit and that the activity is neither duplicative nor solely shareholder-related. For medical or safety work, retain tickets, reports, meetings and decisions without collecting sensitive data unnecessary for the tax purpose. Materiality should connect request, performance, delivery, booking and payment.
Choose allocation keys related to consumption: products, hours, cases, sales, users or studies depending on the service. Headcount and revenue are not universal. Check whether licenses or royalties already include support to avoid a duplicate charge.
Reconcile charges to withholding, VAT, invoices and the agreement. Arm’s-length pricing and documentary deductibility are connected but distinct tests.
Product economic dashboard
Monitor gross and net sales, discounts, COGS, royalties, promotion, medical, regulatory, inventory, expiry, margin and projected true-up. Add registration, study, access and exclusivity milestones. Every deviation should have a cause and owner.
Bridge forecast to actual across volume, price, mix, tender, rebate, FX and supply. A low margin may arise from a principal-controlled concession, a local investment or an operating failure; the bridge prevents automatic conclusions.
For shared products, allocate cost using approved rules and preserve versions. Do not overwrite the business case when launch assumptions change. Forecast accuracy and the age of pending actions indicate control quality.
Audit readiness
Anticipate cross-checks among the study, agreements, health registrations, invoices, trial balance and returns. The authority may ask why a royalty exists, what Mexico receives, how the rate was selected and who performs local functions.
Prepare a product narrative covering rights, FAR, decisions, method and reconciliation. Identify protected documents and a secure response protocol. Do not provide large data sets without an index and explanation.
Sample services and promotional activity before a request arrives. If there is an inconsistency, quantify it and remediate prospectively with evidence rather than manufacturing historical deliverables.
Governance of changes
Require tax review for a new indication, license amendment, registration transfer, new study, distribution change, patient-support program or material discount. Each can change rights, benefit, cost base or risk.
Use a change form stating the business purpose, deciding entity, affected products, expected economics, documents and implementation date. Connect it to ERP, invoicing and statutory filings.
Review open changes quarterly. A regulatory approval may occur months before the agreement or price formula is updated; the log exposes that gap while it can still be corrected.
Illustrative example
A Mexican affiliate funds and performs local studies, develops an access dossier and negotiates a key listing while paying a uniform royalty to the parent. The group must determine whether it acted under global control and budget as a service provider or made decisions and assumed risk deserving additional return. Spending alone does not answer.
If the parent controlled protocol, price and strategy while Mexico executed with reimbursement and markup, the conclusion may differ. Agreements and conduct decide.
Conclusion
Life sciences requires connecting science, regulation and market with economics. Patents, registrations, evidence, promotion and access are distinct pieces that different entities may own or control.
A product-level review prevents mechanical royalties, identifies services and local contributions, and creates a policy that explains launch, maturity and loss of exclusivity.
Request a Life Sciences TP Review to map rights, activities, risks, royalties and product margins with health-regulatory and financial evidence.
Verified official sources
- Mexican Chamber of Deputies, current Income Tax Law, Articles 76, 179 and 180.
- COFEPRIS, Clinical trials.
- COFEPRIS, Pharmacovigilance in Mexico.
- OECD, Transfer Pricing Guidelines 2022, Chapters I, VI and VII.
Verification closed on August 2, 2026. Confirm authorizations, agreements, data and applicable health rules for each product.